


## January 2025

Hikma is a global pharmaceutical company listed on the London Stock Exchange providing customers across North America, MENA and Europe with a broad range of generic, specialty and branded pharmaceutical products. Hikma entered the US market in 1991 and today it is a top-ten supplier of a broad range of injectable, oral, nasal, inhalable and other generic products<sup>1</sup>. Hikma sells its products across the US and Canada.



### Local expertise, global strength



4

Manufacturing plants



2,150+

employees



2

R&D centres

### Manufacturing plants

#### Cherry Hill, New Jersey

Manufactures a broad range of injectable products in various dosage forms, including vials/ampoules, lyophilised products, prefilled syringes, IV bags and emulsions/suspensions

#### Columbus, Ohio

Consists of two manufacturing plants – a general formulations plant and a high containment plant. Manufactures a broad range of non-injectable products, including oral solids, liquids, nasal sprays and inhalation products

#### Dayton, New Jersey

Manufactures compounded sterile injectable products for the US market

### Leading market position in the US

#3

generic injectable manufacturer by volume<sup>2</sup>

#12

supplier of generic non-injectable products<sup>3</sup>

#1

generic nasals manufacturer by volume<sup>4</sup>

### Large injectable portfolio

More than 170 injectable products in the US and consistently launching between 10 to 15 products each year

### CMO capabilities

Our state-of-the-art facility in Columbus, Ohio offers complex manufacturing technologies for CMO, including for oral and nasals. Also our Injectables manufacturing hub in Cherry Hill, NJ provides CMO services

### A diversified portfolio of medicines

We develop, manufacture and distribute a broad range of injectable, oral, nasal and inhalable generic and branded pharmaceutical products, including essential medicines that hospitals, physicians and pharmacists need to treat their patients. Therapeutic areas include:



Anti-infectives



Pain management



Cardiovascular



Oncology



Diabetes (inc. generic GLP-1s)



Allergy



Respiratory

#### References:

1. IQVIA MAT October 2024, includes all generic injectable and non-injectable products by sales
2. IQVIA MAT October 2024, generic injectable products by eache, excludes branded generics and Becton Dickinson
3. IQVIA MAT October 2024, all generic non-injectable products by sales
4. IQVIA MAT October 2024

#### Company information

Chief Executive Officer:  
Riad Mishlawi

Chief Financial Officer:  
Khalid Nablisi

#### Hikma Pharmaceuticals USA

Inc. 200 Connell Drive, 4<sup>th</sup> floor,  
Berkley Heights, NJ 07922

#### Contacts

See [www.hikma.com](http://www.hikma.com) for contact forms